An update on Invivyd, the small biotech company developing an injectable, low-dose monoclonal antibody to protect against Covid-19 infection like a vaccine does, but without the real or perceived limitations of vaccines. I last wrote about Invivyd in this newsletter in August 2025.
On Tuesday, Invivyd reported the results from a Phase 3 study called LIBERTY that demonstrated the superior safety and tolerability of its antibody candidate, VYD2311, compared against Comirnaty, the established mRNA-based Covid vaccine marketed by Pfizer. After six days, 57% of study participants who had VYD2311 injected into the muscle of their upper arm reported headaches, chills, fatigue or pain at the injection site — the typical side effects associated with vaccinations. In the Comirnaty arm of the study, 91% of participants reported the same side effects. The difference was statistically significant. The same study showed VYD2311 was also better tolerated at 56 days, and could be combined safely with Comirnaty.
Continue to STAT+ to read the full story…
